Cognition Therapeutics up on positive data from Alzheimer’s drug study

Cognition Therapeutics

28/06/2023 12:54

** Shares of drug developer Cognition Therapeutics  CGTX.O 
rise 8.4% to $2.71 premarket
    ** CGTX says its experimental drug to treat adults with
mild-to-moderate Alzheimer’s disease met main goals of safety
and tolerability in mid-stage study    
    ** The drug candidate, CT1812, also showed positive impact
on brain function but data not statistically significant - CGTX 
    ** Up to last close, stock up 19% YTD   

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))